

**ALKEM LABORATORIES LTD.**

Regd. Office : " ALKEM HOUSE", Senapati Bapat Marg,
Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022-2495 2955
Email : contact@alkem.com Website : www.alkemlabs.com
CIN no :- U00305MH1973PLC174201



7th March, 2016

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051. Scrip Symbol: ALKEM
---	---

Dear Sirs

Sub: Alkem Laboratories Limited ("Company") receives US FDA approval

This is to inform you that the Company has received Establishment Inspection Report from US Food and Drug Administration (US FDA) after successful inspection of Company's manufacturing plant situated at Mandva, Gujarat, India.

A copy of Press Release is enclosed herewith for your information. Kindly take the same on record.

Sincerely,
For **Alkem Laboratories Limited**


Manish Narang
Sr. V.P. Legal, Company Secretary & Compliance Officer

Encl.: a/a



ALKEM LABORATORIES LTD.

Regd. Office : "ALKEM HOUSE", Senapati Bapat Marg,
Lower Parel, MUMBAI 400 013. Phone : 3982 9999, Fax : 022-2495 2955
Email : contact@alkem.com Website : www.alkemlabs.com
CIN no :- U00305MH1973PLC174201



Press Release

Alkem's Mandva Plant successfully obtains the Establishment Inspection Report from the US FDA

Mumbai, March 7, 2016: Alkem Labs Ltd (Alkem) today announced that its manufacturing plant at Mandva, Gujarat, has successfully obtained the Establishment Inspection Report (EIR) from the US FDA. The plant manufactures Active Pharmaceutical Ingredients (APIs) and was inspected by the US FDA in September 2015.

This facility at Mandva would be Alkem's 6th plant to receive US FDA approval. The Company's other US FDA approved plants include formulation manufacturing facilities at Baddi (Himachal Pradesh, India), Daman (India) and St Louis (Missouri, United States) and API manufacturing facilities at Ankleshwar (Gujarat, India) and California (United States).

Commenting on the development, Prabhat Agrawal, CEO, Alkem said, "This development re-affirms Alkem's focus towards US as its key market and further boosts Alkem's ability to enhance its product offering for this market."

About Alkem Laboratories Ltd.

Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and 55 countries internationally, primarily the United States. In FY15, Alkem was the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IMS SSA MAT March 2015). Also, through FY11 to FY15, Alkem was the third-fastest growing company in terms of sales amongst the 10 largest pharmaceutical companies in the Indian domestic formulations market (Source: IMS SSA MAT March 2015).

Having established itself in the Indian pharmaceutical market, Alkem has expanded internationally through both organic growth and certain strategic acquisitions. The United States is the key market for the company though its products are sold in 55 countries worldwide.

For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com

For further information or queries please contact -

Gagan Borana

Investor Relations – Alkem Laboratories Ltd.

Tel: +91 22 3982 9960 / Mobile: +91 98190 56333

E-mail: gagan.borana@alkem.com